The Binding Site, Inc., has announced the availability of a Proteinase–3 (cANCA) native auto-antigen to the in-vitro diagnostics (IVD) market. Created for use as an integral component in solid phase ELISA-based immunoassay test procedures, this Proteinase–3 (cANCA) native auto-antigen is designed to meet the needs of clinical and life science researchers, medical laboratory professionals, and manufacturers of in-vitro diagnostic (IVD) immunoassay kits and tests for autoimmune conditions.
Autoantibodies to Proteinase–3 are typically found in the sera of patients with active Wegener's granulomatosis, and less often in other types of systemic vasculitis, including microscopic polyangiitis, idiopathic crescentic glomerulonephritis, Churg-Strauss syndrome, and polyarteritis nodosa. Autoantibodies to Proteinase–3 appear to recognize conformational epitopes and have been reported to interfere with inactivation of the enzyme by α1-antitrypsin and also to inhibit proteolytic activity itself. The use of purified Proteinase–3 for the detection of cANCA by solid-phase ELISA has been described in literature since the late 1980s.
Derived and sourced from human neutrophils and tested to be free of HBs-Ag, HCV, HIV-1 & HIV-2, this Proteinase–3 native auto-antigen exhibits a purity level greater than 95%, as assessed by SDS gel electrophoresis. In addition, according to company spokespersons, the product displays high degrees of activity and specificity, while demonstrating exceptional shelf life stability and lot-to-lot consistency. This Proteinase–3 (cANCA) native auto-antigen is available in two separate packaging formats including 1.0 mg and 0.2 mg standard fill vials. Bulk packaging configurations are also available. Learn more about products available from The Binding Site.
Read more
